HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY3295668 erbumine

Also Known As:

(2R,4R)-1-((3-chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - LY3295668 erbumine: 1
  - Piperidines: 17
    - LY3295668 erbumine: 1

Experts

1.	Batist, Gerald: 1 article (01/2021)
2.	Bouganim, Nathaniel: 1 article (01/2021)
3.	Chu, Quincy Siu-Chung: 1 article (01/2021)
4.	Fortier, Caroline: 1 article (01/2021)
5.	Hui, Yu-Hua: 1 article (01/2021)
6.	Kremer, Jill D: 1 article (01/2021)
7.	Lithio, Andrew: 1 article (01/2021)
8.	Smith, Patricia S: 1 article (01/2021)
9.	Stille, John R: 1 article (01/2021)
10.	Yuen, Eunice: 1 article (01/2021)

Related Diseases

1.	Disease Progression 01/01/2021 - "This phase 1 study aimed to determine the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine, an AurA inhibitor, in patients with locally advanced or metastatic solid tumors. Methods Patients with locally advanced or metastatic solid tumors, Eastern Cooperative Oncology Group performance status 0-1, and disease progression after one to four prior treatment regimens were enrolled. "
2.	Neoplasms (Cancer) 01/01/2021 - "Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors." 01/01/2021 - "This phase 1 study aimed to determine the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine, an AurA inhibitor, in patients with locally advanced or metastatic solid tumors. Methods Patients with locally advanced or metastatic solid tumors, Eastern Cooperative Oncology Group performance status 0-1, and disease progression after one to four prior treatment regimens were enrolled. "
3.	Epilepsy (Aura) 01/01/2021 - "This phase 1 study aimed to determine the safety, pharmacokinetics, and antitumor activity of LY3295668 erbumine, an AurA inhibitor, in patients with locally advanced or metastatic solid tumors. Methods Patients with locally advanced or metastatic solid tumors, Eastern Cooperative Oncology Group performance status 0-1, and disease progression after one to four prior treatment regimens were enrolled. "

Related Drugs and Biologics

1.	Aurora Kinase A